Compare Bristol-Myers Squibb Co (BMY) vs J B Hunt Transport Services Inc (JBHT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs J B Hunt Transport Services Inc — how do they compare? Bristol-Myers Squibb Co trades at $58.53 (market cap $116.30B), while J B Hunt Transport Services Inc trades at $276.14 (market cap $26.49B). The key difference: Bristol-Myers Squibb Co is far larger — about 4.4× J B Hunt Transport Services Inc's market cap, and Bristol-Myers Squibb Co pays the higher dividend (4.42%). Which is the better fit depends on your goals.
| BMY | JBHT | |
|---|---|---|
Market Cap | $116.30B | $26.49B |
Sector | Health | Industrials |
52-Week High | $62.37 | $290.07 |
52-Week Low | $42.60 | $130.65 |
Enterprise Value | $152.24B | $27.78B |
Dividend Yield | 4.42% | 0.64% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
JB Hunt Transport Services (JBHT) trades at $283.00, up 1.09% with a bullish technical signal from moving averages. The company has beaten earnings estimates for three consecutive quarters, with Q2 2026 results expected soon. Valuation metrics show a P/E of 43.95 and P/S of 2.25, while profitability remains solid with 5.13% net margin and 16.68% ROE. Analyst consensus is strongly positive with 26 buy ratings and a $280.59 price target.
JBHT demonstrates consistent operational performance with stable cash flow generation, though revenue has declined from 2022 peaks. The stock faces valuation concerns with elevated P/E ratios, while freight market cyclicality presents ongoing business risks. Earnings momentum and strong analyst support provide upside potential, but investors should monitor Q2 earnings results for confirmation of growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About J B Hunt Transport Services Inc
J.B. Hunt Transport Services ranks among the top surface transportation companies in North America by revenue. Its primary operating segments are intermodal delivery, which uses the Class I rail carriers for the underlying line-haul movement of its owned containers (45% of sales in 2021).
Read more on JBHT →
